Creative Biolabs offers a complement-dependent cytotoxicity (CDC) evaluation service that combines advanced biological assays, high-throughput screening platforms, and innovative Fc engineering to accelerate drug discovery, enhance therapeutic potency, and provide critical insights for the efficient development of highly effective antibody candidates.

Introduction

Monoclonal antibodies (mAbs) are complex biotherapeutics whose efficacy often relies on immune effector functions like CDC. CDC is a vital mechanism where specific antibodies trigger the complement cascade, forming the membrane attack complex to lyse target cells, crucial for clearing tumor cells and pathogens. Thorough CDC evaluation is paramount for defining critical quality attributes and validating the mechanism of action of therapeutic antibodies, supporting their development from discovery to clinic.

Service

At Creative Biolabs, our CDC evaluation service provides specific, actionable deliverables crucial for advancing your therapeutic antibody programs. We offer quantifiable potency data, including precise EC₅₀ values, essential for comparing and ranking lead candidates. Our analyses deliver mechanistic insights into your antibody's functional engagement with the complement system, validating its mechanism of action. This data is rigorously documented, providing robust support for new drug submissions and facilitating regulatory compliance.

We also offer strategic guidance for Fc engineering, aiming to optimize complement component 1q (C1q) binding and enhance overall CDC activity, directly addressing challenges in developing high-potency biotherapeutics. By partnering with us, you mitigate preclinical development risks and identify highly effective candidates earlier in the discovery pipeline.

Discover how we can help - Request a consultation.

What We Can Offer

How to Work

Key Advantages

• Customized Assay Development: We offer bespoke assay design, meticulously optimizing every parameter to match your specific antibody, target, and project goals. This ensures the most relevant and precise CDC data for your therapeutic candidate.
• Flexible Assay Formats: Whether you require early-stage screening or detailed mechanistic studies, we provide versatile assay formats, including batch, fed-batch, or continuous mode options for sustained analysis, ensuring maximum yield of critical data points.
• Optimized Reaction Conditions: Our experts fine-tune culture and reaction conditions to maximize the CDC effect, ensuring optimal complement activation and target cell lysis for robust potency measurements.

Explore our CDC evaluation services - Get a quote today.

Representative Data

Summary: This study presents a rational domain engineering framework to optimize receptor binding kinetics, addressing unconsidered endogenous antibody competition during therapeutic antibodies' intracellular trafficking. The two variants' distinct kinetics emphasize the need for precise control over pH-dependent association/dissociation rates in receptor binding. The superior variant is a next-generation platform with enhanced pharmacokinetics and effector functions, aiding the development of biologics with better serum persistence and efficacy.

Fig.1 Assessment of CDC in antibody therapeutics.¹

FAQs

Why Choose Us

Choosing Creative Biolabs for your CDC evaluation means partnering with a leader in antibody characterization. Our distinct advantages are rooted in deep scientific expertise, advanced technological platforms, and an unwavering commitment to quality and client success.

Customer Reviews

"Using Creative Biolabs' CDC evaluation service in our research has significantly improved our ability to confidently select lead candidates. The precise EC50 values and detailed mechanistic insights were invaluable for our oncology program." - Dr. J. Smi***.

"Creative Biolabs helped us understand how to best engineer our antibody's Fc region for enhanced CDC. Their in-depth C1q binding analysis and expert recommendations directly led to a more potent therapeutic, a crucial advantage in a competitive landscape." - C. Lee***.

How to Contact Us

Ready to unlock the full therapeutic potential of your antibodies? Our team of experienced scientists is eager to discuss your specific project needs and provide a tailored solution. Works with us to quickly implement CDC testing - contact us.

Reference

1. Ko, Sanghwan et al. "Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential." Journal of biological engineering vol. 19,1 35. 18 Apr. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s13036-025-00506-y

Loading case studies...

For research use only. Not intended for any clinical use.